SARS-CoV-2 Spike Protein Vaccine (Recombinant) (Novavax) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This SARS-CoV-2 Spike Protein Vaccine (Recombinant) (Novavax) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
25
Registered trials
13
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether SARS-CoV-2 Spike Protein Vaccine (Recombinant) (Novavax) can convert its Prophylactic vaccine, Genetically engineered subunit vaccine profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | SARS-CoV-2 Spike Protein Vaccine (Recombinant) (Novavax) (query alias: NVX-CoV2373) |
|---|---|
| Modality / target | Prophylactic vaccine, Genetically engineered subunit vaccine; Not disclosed; Not disclosed |
| Highest global status | Approved |
| Originator | Not disclosed |
| Active developers | Not disclosed |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06065176 | Phase 4 | Completed | 1188 | Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group |
| NCT06291857 | Phase 3 | Completed | 9320 | Numbers of participants with solicited local and systemic adverse events (AEs) |
| NCT05875701 | Phase 3 | Completed | 147 | Neutralizing Antibody (Nab) for SARS-CoV-2 Wildtype Virus (Wuhan) Responses Expressed as Geometric Mean Titers (GMT) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
Phase 3; n=911; evaluation: not stated. Reported fields: Baseline (Day 1)(Geometric Mean) = 33233.4 Elisa Units per mL (95% Confidence Interval, 28863.0 - 38265.4); Baseline (Day 1)(Geometric Mean) = 36142.6 Elisa Units per mL (95% Confidence Interval, 31430.8 - 41560.8); -
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Novavax COVID-19 Vaccine(s) as Second or Subsequent Booster After mRNA Vaccines in Individuals 18 to 49 Years of Age
Phase 3; n=147; evaluation: not stated. Reported fields: Date of 1st booster dose (Study 307)(Geometric Mean) = 159.5 titers (95% Confidence Interval, 94.3 - 269.9); -; -
Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial
Phase 3; n=129; evaluation: Positive. Reported fields: AE(Solicited local) = 73.6 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
SARS-CoV-2 Spike Protein Vaccine (Recombinant) (Novavax) addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Prophylactic vaccine, Genetically engineered subunit vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-08-09 | SK bioscience Announces Equity Investment in Novavax to Strengthen Strategic Partnership | Phase 3 | Financial terms not disclosed |
| 2020-08-07 | Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan | Approved | Financial terms not disclosed |
| 2020-08-06 | Novavax and Serum Institute of India Announce Development and Commercial Collaboration | Phase 1/2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
